Integrated BioPharma director awarded 50,000 options

Integrated BioPharma Inc. director William H. Milmoe received a grant of stock options to acquire 50,000 shares of Common Stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Integrated BioPharma Inc. director William H. Milmoe received a grant of stock options to acquire 50,000 shares of Common Stock. The options have an exercise price of $0.19 per share and were awarded at no cost to him.

The options vest in four equal installments of 12,500 options each on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, and expire on June 24, 2036. This is a routine compensation-related award rather than an open-market trade.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Milmoe William H.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 50,000 contracts (Direct)

Footnotes (1)

F1. The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027.

Key Figures

Options granted: 50,000 options Exercise price: $0.19 per share Post-grant derivative holdings: 50,000 options +2 more

5 metrics

Options granted 50,000 options Stock Option (Right to Buy) grant to director

Exercise price $0.19 per share Conversion or exercise price for the options

Post-grant derivative holdings 50,000 options Total derivative securities following the transaction

Vesting installment size 12,500 options Each of four vesting dates from 2026 to 2027

Option expiration date June 24, 2036 Final date the options may be exercised

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, Common Stock

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 0.1900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The stock options vest and become exercisable in four equal installments"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did INBP director William H. Milmoe report?

Director William H. Milmoe reported receiving a grant of 50,000 stock options. These options give him the right to buy Integrated BioPharma Common Stock as part of his compensation, rather than reflecting an open-market purchase or sale of existing shares.

How many stock options were granted to the INBP director and at what price?

William H. Milmoe was granted 50,000 stock options at an exercise price of $0.19 per share. This means he can buy up to 50,000 Integrated BioPharma shares at $0.19 if and when the options are vested and exercised.

When do William H. Milmoe’s INBP stock options vest?

The options vest in four equal installments of 12,500 each. Vesting dates are September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, gradually giving Milmoe the right to exercise the options over this period.

When do the newly granted INBP stock options expire?

The granted stock options expire on June 24, 2036. After this expiration date, William H. Milmoe can no longer exercise the options to buy Integrated BioPharma Common Stock, even if they have vested and were not previously exercised.

Is this INBP Form 4 transaction an open-market stock purchase or sale?

No, this transaction is a grant of stock options as compensation, coded as a grant or award. It does not represent Milmoe buying or selling Integrated BioPharma shares in the open market, but rather receiving rights to buy shares later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/25/2026 - 11:27 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Milmoe William H.

(Last)

(First)

(Middle)

109 SE 5TH AVENUE

SECOND FLOOR

(Street)

DELRAY BEACH

FLORIDA

33483

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTEGRATED BIOPHARMA INC [ INBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.19	06/24/2026		A		50,000		⁽¹⁾	06/24/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027.

	/s/ William Milmoe	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR